Ontologies for Intelligent e-Theraoy: Application to Obesity

[EN] In this paper we propose a new approach for mental e-health treatments named intelligent e-therapy (e-it) with capabilities for ambient intelligence and ubiquitous computing. The proposed e-it system supposes an evolution of cybertherapy and telepsychology tools used up to now. The e-it system is based in a knowledge base that includes all the knowledge related to the disorder and its treatment. We introduce the use of ontologies as the best option for the design of this knowledge base. We also present a fist e-it system for obesity treatment called etiobeZaragozá Álvarez, I.; Guixeres Provinciale, J.; Alcañiz Raya, ML. (2009). Ontologies for Intelligent e-Theraoy: Application to Obesity. Lecture Notes in Computer Science. 5518:894-901. doi:10.1007/978-3-642-02481-8_136S8949015518Baños, R.M., Botella, C., Perpiñá, C., Alcañiz, M., Lozano, J.A., Osma, J., Gallardo, M.: Virtual reality treatment of flying phobia. IEEE Transactions on Information Technology in Biomedicine 6(3), 206–212 (2002)Botella, C., Baños, R.M., Perpiña, C., et al.: Virtual reality treatment of claustrophobia: a case report. Behaviour Research & Therapy 36, 239–246 (1998)Hu, B., Dasmahapatra, S., Dupplaw, D., Lewis, P., Shadbolt, N.: Reflections on a medical ontology. International Journal of Human- Computer Studies 65(2007), 569–582 (2007)Rubin, D.L., Shah, N.H., Noy, N.F.: Biomedical ontologies: a functional perspective. Briefings in bioinformatics 9(1), 75–90 (2007)Stevens, R., Egaña Aranguren, M., Wolstencroft, K., Sattler, U., Drummond, N., Horridge, M., Rector, A.: Using OWL to model biological knowledge. International Journal of Human-Computer Studies 65(2007), 583–594 (2007)Park, S., Lee, J.K.: Rule identification using ontology while acquiring rules from Web pages. International Journal of Human-Computer Studies 65(2007), 644–658 (2007)Clark, K.L., McCabe, F.G.: Ontology schema for an agent belief store. International Journal of Human-Computer Studies 65(2007), 625–643 (2007)Gruber, T.R.: A Translation Approach to Portable Ontology Specifications. Knowledge Acquisition 5(2), 199–220 (1993)Franco, C., Bengtsson, B., Johannsson, G.: The GH/IGF-1 Axis in Obesity: Physiological and Pathological aspects. Metabolic syndrome and Related Disorders 4, 51–56 (2006

Effects of Large CP violating phases on g_{\m}-2 in MSSM

Effects of CP violation on the supersymmetric electro-weak correction to the anomalous magnetic moment of the muon are investigated with the most general allowed set of CP violating phases in MSSM. The analysis includes contributions from the chargino and the neutralino exchanges to the muon anomaly. The supersymmetric contributions depend only on specific combinations of CP phases. The independent set of such phases is classified. We analyse the effects of the phases under the EDM constraints and show that large CP violating phases can drastically affect the magnitude of the supersymmetric electro-weak contribution to $a_{\mu}$ and may even affect its overall sign.Comment: 26 pages Latex file including 4 figure

Drug-gene interactions of antihypertensive medications and risk of incident cardiovascular disease: A pharmacogenomics study from the CHARGE consortium

Background Hypertension is a major risk factor for a spectrum of cardiovascular diseases (CVD), including myocardial infarction, sudden death, and stroke. In the US, over 65 million people have high blood pressure and a large proportion of these individuals are prescribed antihypertensive medications. Although large long-term clinical trials conducted in the last several decades have identified a number of effective antihypertensive treatments that reduce the risk of future clinical complications, responses to therapy and protection from cardiovascular events vary among individuals. Methods Using a genome-wide association study among 21,267 participants with pharmaceutically treated hypertension, we explored the hypothesis that genetic variants might influence or modify the effectiveness of common antihypertensive therapies on the risk ofmajor cardiovascular outcomes. The classes of drug treatments included angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, and diuretics. In the setting of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, each study performed array-based genome-wide genotyping, imputed to HapMap Phase II reference panels, and used additive genetic models in proportional hazards or logistic regressionmodels to evaluate drug-gene interactions for each of four therapeutic drug classes. We used meta-analysis to combine study-specific interaction estimates for approximately 2 million single nucleotide polymorphisms (SNPs) in a discovery analysis among 15,375 European Ancestry participants (3,527 CVD cases) with targeted follow-up in a case-only study of 1,751 European Ancestry GenHAT participants as well as among 4,141 African-Americans (1,267 CVD cases). Results Although drug-SNP interactions were biologically plausible, exposures and outcomes were well measured, and power was sufficient to detect modest interactions, we did not identify any statistically significant interactions from the four antihypertensive therapy meta-analyses (Pinteraction > 5.0×10-8). Similarly, findings were null for meta-analyses restricted to 66 SNPs with significant main effects on coronary artery disease or blood pressure from large published genom

Gene-gene Interaction Analyses for Atrial Fibrillation

Atrial fibrillation (AF) is a heritable disease that affects more than thirty million individuals worldwide. Extensive efforts have been devoted to the study of genetic determinants of AF. The objective of our study is to examine the effect of gene-gene interaction on AF susceptibility. We performed a large-scale association analysis of gene-gene interactions with AF in 8,173 AF cases, and 65,237 AF-free referents collected from 15 studies for discovery. We examined putative interactions between genome-wide SNPs and 17 known AF-related SNPs. The top interactions were then tested for association in a

Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium

It is unclear whether genetic markers interact with risk factors to influence atrial fibrillation (AF) risk. We performed genome-wide interaction analyses between genetic variants and age, sex, hypertension, and body mass index in the AFGen Consortium. Study-specific results were combined using meta-analysis (88,383 individuals of European descent, including 7,292 with AF). Variants with nominal interaction associations in the discovery analysis were tested for association in four independent studies (131,441 individuals, including 5,722 with AF). In the discovery analysis, the AF risk associated with the minor rs6817105 allele (at the PITX2 locus) was greater among subjects ≤ 65 years of age than among those > 65 years (interaction p-value = 4.0 × 10-5). The interaction p-value exceeded genome-wide significance in combined discovery and replication analyses (interaction p-value = 1.7 × 10-8). We observed one genome-wide significant interaction with body mass index and several suggestive interactions with age, sex, and body mass index in the discovery analysis. However, none was replicated in the independent sample. Our findings suggest that the pathogenesis of AF may differ according to age in individuals of European descent, but we did not observe evidence of statistically significant genetic interactions with sex, body mass index, or hypertension on AF risk